0001005201-19-000078.txt : 20190509 0001005201-19-000078.hdr.sgml : 20190509 20190509113107 ACCESSION NUMBER: 0001005201-19-000078 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190507 FILED AS OF DATE: 20190509 DATE AS OF CHANGE: 20190509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tyree James L CENTRAL INDEX KEY: 0001324991 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-13111 FILM NUMBER: 19809466 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-6400 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Assertio Therapeutics, Inc CENTRAL INDEX KEY: 0001005201 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943229046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 SOUTH SAUNDERS RD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 BUSINESS PHONE: (224) 419-7106 MAIL ADDRESS: STREET 1: 100 SOUTH SAUNDERS RD STREET 2: SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 FORMER COMPANY: FORMER CONFORMED NAME: DEPOMED INC DATE OF NAME CHANGE: 19970408 4 1 wf-form4_155741585078890.xml FORM 4 X0306 4 2019-05-07 0 0001005201 Assertio Therapeutics, Inc ASRT 0001324991 Tyree James L ASSERTIO THERAPEUTICS, INC. 100 SOUTH SAUNDERS ROAD, SUITE 300 LAKE FOREST IL 60045 1 0 0 0 Common Stock 2019-05-07 4 A 0 39584 0 A 49340 D Common Stock 2019-05-08 4 M 0 31250 0 A 80590 D Restricted Stock Units 0.0 2019-05-08 4 M 0 31250 0 D 2019-05-08 2019-05-08 Common Stock 31250.0 0 D Restricted stock units that vest in full on the first anniversary of the grant date. Since the date of the reporting person's last ownership report, he transferred 9,756 shares of the Registrant's common stock pursuant to a domestic relations order. The reporting person no longer reports these securities as beneficially owned by him. Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. /s/ Erin R. McQuade, attorney in fact 2019-05-09